期刊文献+
共找到5篇文章
< 1 >
每页显示 20 50 100
中成药与西药联合应用时的相互影响 被引量:2
1
作者 崔建丽 《实用医技杂志》 1996年第4期261-262,共2页
中成药与西药联合应用治疗疾病,在临床上日益广泛,根据翻阅处方和病历,结合查出的一切问题,用药质量,以减少毒引反应的发生。现将有关资料简要整理,供临床参考。 一、含有石膏(ca^(2+))、海螺蛸(ca^(2+))、滑石粉(mg^(6+))、明矾(Al^(3... 中成药与西药联合应用治疗疾病,在临床上日益广泛,根据翻阅处方和病历,结合查出的一切问题,用药质量,以减少毒引反应的发生。现将有关资料简要整理,供临床参考。 一、含有石膏(ca^(2+))、海螺蛸(ca^(2+))、滑石粉(mg^(6+))、明矾(Al^(3+))等的中成药,如:桔红丸、明目上清丸、牛黄解毒丸等,不宜与四不素族抗生素及异烟肼等同服。 展开更多
关键词 中成药 西药 药理相互作用
下载PDF
喹诺酮类药物的回顾与展望 被引量:2
2
作者 王雪明 陆维艾 《中国药物与临床》 CAS 2002年第3期172-173,共2页
关键词 喹诺酮类药物 不良反应 药理 药理相互作用 药物结构
下载PDF
Management of hypertensive crises in the elderly 被引量:3
3
作者 Abbas Alshami Carlos Romero +1 位作者 America Avila Joseph Varon 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2018年第7期514-522,共9页
Hypertensive crises are elevations of blood pressure higher than 180/120 mmHg. These can be urgent or emergent, depending on the presence of end organ damage. The clinical presentation of hypertensive crises is quite ... Hypertensive crises are elevations of blood pressure higher than 180/120 mmHg. These can be urgent or emergent, depending on the presence of end organ damage. The clinical presentation of hypertensive crises is quite variable in elderly patients, and clinicians must be suspicious of non-specific symptoms. Managing hypertensive crises in elderly patients needs meticulous knowledge of the pathophysiological changes in them, pharmacological options, pharmacokinetics of the medications used, their side effects, and their interactions with other medications. Clevidipine, nicardipine, labetalol, esmolol, and fenoldopam are among the preferred choices in the elderly due to their efficacy and tolerability. Nitroprusside, hydralazine, and nifedipine should be avoided, unless there are no other options available, due to the high risk of complications and unpredictable responses. 展开更多
关键词 Beta-blockers Calcium channel blockers CLEVIDIPINE Elderly ESMOLOL FENOLDOPAM Hypertensive crises LABETALOL NICARDIPINE Nitroprusside
下载PDF
Individually administered or co-prescribed thiopurines and mesalamines for inflammatory bowel disease
4
作者 Giovanni C Actis Rinaldo Pellicano +5 位作者 Mario Rizzetto Muhammad Ayoubi Nicola Leone Gianfranco Tappero Paola Pazienza Floriano Rosina 《World Journal of Gastroenterology》 SCIE CAS CSCD 2009年第12期1420-1426,共7页
Data from both basic research and clinical experience continue to suggest that mesalamines and thioputines are effective and efficient for the maintenance of remission of inflammatory bowel diseases. Several decades f... Data from both basic research and clinical experience continue to suggest that mesalamines and thioputines are effective and efficient for the maintenance of remission of inflammatory bowel diseases. Several decades following the formalization of their indications, attention on these two drugs has been fostered by recent achievements. Demonstration of the ability of mesalamine to activate a colonocyte differentiation factor has shed light on its chemopreventive effects on colorectal cancer; in addition to their anti-proliferative efficacy, thiopurines have been shown to be specific regulators of apoptosis. The two drugs are often coadministered in clinical practice. Recent advancements have shown that mesalamines exert a positive synergism in this context, insofar as they can inhibit sidemethylation of thiopurines and hasten the function of the main immunosuppressive pathways. Considering that up to 40% of patients cannot tolerate thiopurines, such renovated targets have stimulated efforts to improve compliance by research on the toxicity mechanisms. The definition of genetic polymorphisms in the enzymes of thiopurine metabolism, and the uncovering of synergistic drug interactions, such as that with allopurinol, are just two of the results of such efforts. Interaction between basic research and clinical practice has continued to inform indications and refine the prescriptions of mesalamines and thiopurines; these have not been restrained (they have been implemented in some cases) by the advent of the novel biological molecules with anti-cytokine activity. 展开更多
关键词 Inflammatory bowel disease MESALAMINE THIOPURINES AZATHIOPRINE REMISSION Drug toxicity
下载PDF
A new sample preparation method for the determination of acyclovir by RP-HPLC:application to a drug-drug interaction study between gefitinib and acyclovir in rats
5
作者 Ying Li Zhou Wen +3 位作者 Yongling Liu Zhibing Zhao Lei Wang Zeneng Cheng 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2021年第6期495-504,共10页
The assay of acyclovir in plasma seems to be a challenge because of its high hydrophily.In our present study,a reversed-phase high-performance liquid chromatography(RP-HPLC)method for the determination of acyclovir in... The assay of acyclovir in plasma seems to be a challenge because of its high hydrophily.In our present study,a reversed-phase high-performance liquid chromatography(RP-HPLC)method for the determination of acyclovir in rat plasma was described and validated in drug-drug interaction(DDI)between gefitinib and acyclovir in rats.The analytes were separated with gradient elution on C18 column(4.6 mm×250 mm,5μm),and the peaks were recorded using ultraviolet detector at a wavelength of 254 nm.Protein precipitation followed by methyl tertiary butyl ether extraction was used for sample preparation.The calibration curve was established between 0.2 and 40μg/mL(r^(2)=0.9999).The intra-and inter-day precisions were all less than 8%,and all the biases were not more than 10%.This new method was successfully applied to a DDI study between gefitinib and acyclovir in rats.Gefitinib up-regulated the absorption of acyclovir by about three times,and our findings guided the clinical co-administration of epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs)with acyclovir. 展开更多
关键词 ACYCLOVIR High-performance liquid chromatography Sample preparation ABSORPTION Drug-drug interaction
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部